Blogarama: The Oldest Blog Directory

NEWARK, Calif., May 11, 2016 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies to treat metabolic… Read More

NEWARK, Calif., Feb. 01, 2017 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for specialty and… Read More

NEWARK, Calif., March 23, 2017 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company developing therapies to treat specialty and orpha… Read More

Cymabay Therapeutics Inc (NDAQ:CBAY) Price Target & New Coverage by Suntrust Robinson In analysts report shared with investors on Friday, 18 August, research professionals at Suntrust… Read More

NEWARK, Calif., Oct. 23, 2017 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and othe… Read More

Checchi Capital Advisers Llc decreased Apple Inc (AAPL) stake by 11.82% reported in 2017Q2 SEC filing. Checchi Capital Advisers Llc sold 6,977 shares as Apple Inc (AAPL)’s stock rose… Read More

Conference call and webcast today at 4:30p.m. ET NEWARK, Calif., March 15, 2018 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company… Read More

Paris (ots/PRNewswire) – Das NASH Education Program[TM] wurde entwickelt, um Ärzte und potenzielle Patienten weltweit mit Aufklärung und Schulung im Kampf gegen eine an H… Read More

Tanzeel Akhtar , Benzinga Staff Writer {{following ? CymaBay Therapeutics (NASDAQCBAY) announced results from an ongoing 52-week Phase 2b dose-ranging, paired liver biopsy study of "selade… Read More

MasterTux / Pixabay Stocks continue to be whipsawed by sudden upward, then plunging, prices, only to reverse direction again as political and economic uncertainty reigns supreme. Here are fo… Read More

Read More

( click to enlarge )CymaBay Therapeutics Inc (NASDAQ:CBAY) price broke out of a bottom/accumulation pattern accompanied by strong volume on Friday and is now trading in the gap zone. This br… Read More

The most recent report on Hypercholesterolemia Treatment Market issued by DecisionDatabases, numerous aspects of the current market scenario has been taken into consideration and a… Read More

Buy Now The metabolic disorders drugs market comprises of sale of metabolic disorders& drugs and associated to services provided by organisations that produce drugs to cure metabolic dis… Read More

The metabolic disorders drugs market comprises of sale of metabolic disorders& drugs and associated to services provided by organisations that produce drugs to cure metabolic disorders d… Read More

Buy Now The metabolic disorders drugs market comprises of sale of metabolic disorders& drugs and associated to services provided by organisations that produce drugs to cure metabolic dis… Read More

Penny stocks can be a risky bet. But with that risk comes the potential for high reward. And biotech penny stocks have been some of the most rewarding in 2020. The hunt for a coronavirus va… Read More

The best stocks with 1,000% upside potential may give your portfolio a huge boost over the coming months. In fact, investors are searching for diamonds in the rough as the stock market faces… Read More

Delveinsight Business Research LLP As per DelveInsight, the Primary Biliary Cirrhosis market is expected to grow in the coming years owing to the increase in the prevalent cases of Pri… Read More

Las Vega (Nevada), United States //— As per DelveInsight’s assessment, globally, Primary Biliary Cirrhosis pipeline constitutes 25+ key companies continuously working towards de… Read More

Read More

DelveInsight Business Research LLP DelveInsight’s “Liver Cirrhosis – Market Insights, Epidemiology and Market Forecast – 2032” report delivers an in-depth… Read More

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Liver Cirrhosis pipeline constitutes 50+ key companies continuously working towards developing 50+ Live… Read More

Read More